A Pharmacodynamic Study of a Personalized Strategy for P2Y12 Inhibition Versus Ticagrelor in Reducing Ischemic and Bleeding Risk

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 120 participants.

Also called NCT02044146

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2/3
Enrolled
  • 120 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02044146
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Canada (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02044146. Randomized; double masking; primary purpose treatment. Start 2014-09 (registry gives no type); primary completion 2016-10 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Pharmacodynamic Study of a Personalized Strategy for P2Y12 Inhibition Versus Ticagrelor in Reducing Ischemic and Bleeding Risk
Acronym
RAPID MANAGE
Condition
Acute Coronary Syndrome
Intervention (Drug)
Ticagrelor, Prasugrel, Clopidogrel
Lead sponsor
Ottawa Heart Institute Research Corporation (class: other)
Collaborator
Canadian Institutes of Health Research (CIHR) (class: other government)

Record details

Record id
cardio:ct-nct02044146
Content hash
e4855bdc8bac6cbc53adc6da0712df89102ce8d024ff30e9904438de04f70756